» Articles » PMID: 11861826

Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins

Overview
Journal J Virol
Date 2002 Feb 28
PMID 11861826
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

In virus-infected cells, the envelope glycoprotein (Env) precursor, gp160, of human immunodeficiency virus type 1 is cleaved by cellular proteases into a fusion-competent gp120-gp41 heterodimer in which the two subunits are noncovalently associated. However, cleavage can be inefficient when recombinant Env is expressed at high levels, either as a full-length gp160 or as a soluble gp140 truncated immediately N-terminal to the transmembrane domain. We have explored several methods for obtaining fully cleaved Env for use as a vaccine antigen. We tested whether purified Env could be enzymatically digested with purified protease in vitro. Plasmin efficiently cleaved the Env precursor but also cut at a second site in gp120, most probably the V3 loop. In contrast, a soluble form of furin was specific for the gp120-gp41 cleavage site but cleaved inefficiently. Coexpression of Env with the full-length or soluble form of furin enhanced Env cleavage but also reduced Env expression. When the Env cleavage site (REKR) was mutated in order to see if its use by cellular proteases could be enhanced, several mutants were found to be processed more efficiently than the wild-type protein. The optimal cleavage site sequences were RRRRRR, RRRRKR, and RRRKKR. These mutations did not significantly alter the capacity of the Env protein to mediate fusion, so they have not radically perturbed Env structure. Furthermore, unlike that of wild-type Env, expression of the cleavage site mutants was not significantly reduced by furin coexpression. Coexpression of Env cleavage site mutants and furin is therefore a useful method for obtaining high-level expression of processed Env.

Citing Articles

mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies.

Guenaga J, Alirezaei M, Feng Y, Alameh M, Lee W, Baboo S Front Immunol. 2024; 15:1426232.

PMID: 39119336 PMC: 11306127. DOI: 10.3389/fimmu.2024.1426232.


A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1.

Jain S, Uritskiy G, Mahalingam M, Batra H, Chand S, Trinh H Elife. 2024; 13.

PMID: 38619110 PMC: 11018346. DOI: 10.7554/eLife.92379.


Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A NPJ Vaccines. 2024; 9(1):74.

PMID: 38582771 PMC: 10998906. DOI: 10.1038/s41541-024-00862-8.


New Insights into HIV Life Cycle, Th1/Th2 Shift during HIV Infection and Preferential Virus Infection of Th2 Cells: Implications of Early HIV Treatment Initiation and Care.

Hokello J, Tyagi K, Owor R, Sharma A, Bhushan A, Daniel R Life (Basel). 2024; 14(1).

PMID: 38255719 PMC: 10817636. DOI: 10.3390/life14010104.


Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.

Perdiguero B, Hauser A, Gomez C, Peterhoff D, Sideris E, Sorzano C Front Immunol. 2023; 14:1270908.

PMID: 38045703 PMC: 10690772. DOI: 10.3389/fimmu.2023.1270908.


References
1.
Trkola A, Dragic T, Arthos J, Binley J, Olson W, Allaway G . CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996; 384(6605):184-7. DOI: 10.1038/384184a0. View

2.
Morikawa Y, Barsov E, Jones I . Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol. 1993; 67(6):3601-4. PMC: 237708. DOI: 10.1128/JVI.67.6.3601-3604.1993. View

3.
Willey R, Klimkait T, Frucht D, Bonifacino J, Martin M . Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology. 1991; 184(1):319-29. DOI: 10.1016/0042-6822(91)90848-6. View

4.
Yang X, Florin L, Farzan M, Kolchinsky P, Kwong P, Sodroski J . Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol. 2000; 74(10):4746-54. PMC: 111997. DOI: 10.1128/jvi.74.10.4746-4754.2000. View

5.
Moore J, McKeating J, Weiss R, Sattentau Q . Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990; 250(4984):1139-42. DOI: 10.1126/science.2251501. View